

## Corrigendum

# OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study – CORRIGENDUM

Guy Boudreau<sup>1</sup>, Ian Finkelstein<sup>2</sup>, Corrie Graboski<sup>3</sup>, May Ong<sup>4</sup>, Suzanne Christie<sup>5</sup>, Katherine Sommer<sup>6</sup>, Meetu Bhogal<sup>7</sup>, Goran Davidovic<sup>7</sup> and Werner J. Becker<sup>8</sup>

<sup>1</sup>Centre Hospitalier Universitaire de Montréal (CHUM), Montréal, Quebec, Canada, <sup>2</sup>Toronto Headache & Pain Clinic, Toronto, Ontario, Canada, <sup>3</sup>Island Health, Brentwood Bay, British Columbia, Canada, <sup>4</sup>St Paul Hospital, Vancouver, British Columbia, Canada, <sup>5</sup>University of Ottawa (Neurology), Ottawa, Ontario, Canada, <sup>6</sup>AbbVie Inc., Marlow, Buckinghamshire, UK, <sup>7</sup>AbbVie Inc., Markham, Ontario, Canada and <sup>8</sup>Department of Clinical Sciences, University of Calgary, Calgary, Alberta, Canada

DOI: <https://doi.org/10.1017/cjn.2021.153>; first published online by Cambridge University Press, 5 July 2021.

In the original publication of the above article,<sup>1</sup> the following errors were identified:

- On page 4, in the 2<sup>nd</sup> paragraph of the Baseline Demographics, CM History, and Medication Use History section, the denominator for the total population (n=184) is presented when it should be the number of yes responses (n=145). The correct values for antidepressants and anticonvulsants should be 90/145 (62.1%) and 81/145 (55.9%), respectively.
- On page 5 in Table 1 the Acute Medication Use row, the extraneous n (%) should be deleted.
- On page 6, in Table 2A Tx 3 to Tx 4 for 12 weeks 20 (20.0) should be replaced with 30 (20.0).
- On page 6, in Table 2B the mean (SD) total dose for Tx3 of 172 (18) should be replaced with 172 (19).
- On page 6, on the 2<sup>nd</sup> paragraph of column 1, “Tx7/Final Visit”, Final Visit should be deleted.
- On page 6, on the 1<sup>st</sup> paragraph of column 2 the SD for mean change in moderate/severe headache days should be changed from 5.6 (7.0) to 5.6 (7.1).
- On page 6, on the 1<sup>st</sup> paragraph of column 2, “Tx7/Final Visit”, Final Visit should be deleted.
- On page 7, Figure 2 footnote A to be revised to read: For mean MSQ scores, n (missing) data for role restrictive, role preventive, and emotional function at baseline and Tx4 were 184 (0) and 150 (0), respectively. The n (missing) for the final visit were 143 (41) for role restrictive and role preventive and 142 (42) for emotional function.
- On page 7, Figure 2 footnote B to be revised to read: For mean change from baseline MSQ scores, n (missing) data for role restrictive, role preventive, and emotional function at baseline and Tx4 were 184 (0) and 150 (0), respectively. The n (missing) for the final visit were 143 (41) for role restrictive and role preventive and 142 (42) for emotional function; within group minimal important differences for MSQ v. 2.1 are displayed for reference<sup>37</sup>. Error bars represent standard deviations. Statistical significance is shown as \*p < 0.0001. n, number of participants; Tx, treatment.
- On page 7, column 1, paragraph 1, line 4, “Tx7/” should be deleted.
- On page 7, column 2, line 1, “Tx7/” should be deleted.
- On page 8, Figure 3 footnote, 3<sup>rd</sup> line from end “Missing data include . . . final visit” should be revised to read “The n (missing) data for baseline, Tx1, Tx2, Tx3, Tx4, Tx7, and final visit were 162 (22), 150 (34), 142 (32), 134 (29), 121 (29), 104 (24), and 126 (58).”
- On page 8, the last sentence of the footnote for Figure 3 should be updated from “Participants with <5 d of diary data . . .” to “Participants with <15 d of diary data . . .”
- On page 8, in 2<sup>nd</sup> paragraph of the 1<sup>st</sup> column the control of headache severity results should be updated from “103/123 83.7% [Tx7]” to “100/120 83.3% [final visit].”
- On page 9, Figure 4 A-C, Change Final Visit to Last Visit.
- On page 9, Figure 4 footnote penultimate sentence “Missing data include . . . panels (A) (C), should be revised to read “The n (missing) data for Tx2, Tx3, Tx4, Tx7, and last visit were 174 (0), 161 (2), 150 (0), 127 (1), and 141 (43), respectively.”
- On page 10, in Table 3, insert row “Influenza 6 (3.3) 6 events” above Bronchitis and move Brow ptosis to above Pneumonia.
- On page 10, in Table 3 update Bronchitis to 5 (2.7%) 5 events, Pneumonia to 3 (1.6%) 3 events.
- On page 10, in 2<sup>nd</sup> paragraph of column 2 replace “final visit” with “last injection.”
- On page 10, in 3<sup>rd</sup> paragraph of column 2 replace “discounted” with “discontinued.”

## Reference

1. Boudreau G, Finkelstein I, Graboski C, et al. OnabotulinumtoxinA Improves Quality of Life in Chronic Migraine: The PREDICT Study. *Can J Neurol Sci.* 2022;49(4):540–552. doi: [10.1017/cjn.2021.153](https://doi.org/10.1017/cjn.2021.153)